C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens

Affiliation auteurs!!!! Error affiliation !!!!
TitreC-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens
Type de publicationJournal Article
Year of Publication2020
AuteursTabernero J., E. Fernandez E, Ghiringhelli F., Folprecht G., Curigliano G., Siena S., Cremolini C., Sobrero A., Kwiatek M., S. Keranen R, Ahn D., Punt C., Laurent D., Ferrara M., Pellacani A., Capriati A.
JournalANNALS OF ONCOLOGY
Volume31
PaginationS115
Date PublishedJUL
Type of ArticleMeeting Abstract
ISSN0923-7534
DOI10.1016/j.annonc.2020.04.161